Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,001)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04238715 | A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion | completed | Phase 2 | 63 | Eisai Co., Ltd.INDUSTRY | 2 | Mar 2, 2026 | clinicaltrials |
| NCT03828799 | Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer(FOLFIRINOX-R) | completed | Phase 1 / Phase 2 | 13 | Institut du Cancer de Montpellier - Val d'AurelleOTHER |
| 1 |
| Feb 27, 2026 |
| clinicaltrials |
| NCT04526106 | REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 490 | Elevar TherapeuticsINDUSTRY | 13 | Feb 27, 2026 | clinicaltrials |
| NCT04945720 | Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma | completed | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT02705196 | LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer | completed | Phase 1 / Phase 2 | 51 | Lokon Pharma ABINDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT04233567 | Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations | completed | Phase 2 | 17 | Sameek RoychowdhuryOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT04426669 | A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering | completed | Phase 1 / Phase 2 | 23 | Intima Bioscience, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04469556 | Pancreatic Adenocarcinoma Signature Stratification for Treatment(PASS-01) | completed | Phase 2 | 150 | University Health Network, TorontoOTHER | 2 | Feb 20, 2026 | clinicaltrials |
| NCT03463876 | A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE) | completed | Phase 2 | 190 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03785873 | Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer | completed | Phase 1 / Phase 2 | 34 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT05116085 | Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer | completed | Phase 2 | 33 | BeiGeneINDUSTRY | 1 | Feb 13, 2026 | clinicaltrials |
| NCT03993353 | Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer | completed | Phase 2 | 7 | University of California, San DiegoOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03983057 | Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer | completed | Phase 2 | 392 | Zhejiang UniversityOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT03365882 | S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 240 | SWOG Cancer Research NetworkNETWORK | 2 | Feb 10, 2026 | clinicaltrials |
| NCT04109924 | TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study | completed | Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT03693807 | A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma | completed | Phase 2 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT00208260 | Intensified Chemotherapy in CRC After Resection of Liver Metastases | completed | Phase 2 / Phase 3 | 124 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT00556413 | Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 42 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03211416 | Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer | completed | Phase 1 / Phase 2 | 37 | Roswell Park Cancer InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03008278 | Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Feb 3, 2026 | clinicaltrials |
| NCT03092895 | A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC | completed | Phase 2 | 157 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT03264404 | Azacitidine and Pembrolizumab in Pancreatic Cancer | completed | Phase 2 | 36 | Susan E. BatesOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT04524702 | Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer | completed | Phase 2 | 10 | Emory UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05166239 | HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT | completed | Phase 2 | 66 | Peking UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05641896 | Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers(18F-FAPI-74 GI) | completed | Phase 2 | 109 | SOFIEINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04505553 | Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer | completed | Phase 2 | 78 | University of WashingtonOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04550624 | Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma | completed | Phase 2 | 27 | Shanghai Jiahui International HospitalOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT00826540 | Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 83 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05254847 | Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC | completed | Phase 2 | 65 | Fudan UniversityOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05153785 | Perioperative Intravenous Lidocaine in Liver Surgery | completed | Phase 2 / Phase 3 | 124 | Lund University HospitalOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT05349331 | Watch and Wait and Surgical Treatment for Clinical Complete Responders After Non-Curative Therapy for Hepatocellular Carcinoma(WATCH) | completed | Phase 2 | 74 | Sun Yat-sen UniversityOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT04744831 | Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer(DESTINY-CRC02) | completed | Phase 2 | 122 | Daiichi SankyoINDUSTRY | 10 | Jan 14, 2026 | clinicaltrials |
| NCT05002270 | JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation | completed | Phase 1 / Phase 2 | 29 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05337137 | A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer(RELATIVITY-106) | completed | Phase 1 / Phase 2 | 83 | Bristol-Myers SquibbINDUSTRY | 15 | Jan 12, 2026 | clinicaltrials |
| NCT04567615 | A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors | completed | Phase 2 | 266 | Bristol-Myers SquibbINDUSTRY | 17 | Jan 8, 2026 | clinicaltrials |
| NCT05348811 | HAIC Combined With Donafenib and Sintilimab for Unresectable ICC | completed | Phase 2 | 25 | Zhongda HospitalOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03199274 | Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer | completed | Phase 2 | 104 | Thomas Jefferson UniversityOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT05215379 | Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer | completed | Phase 2 / Phase 3 | 201 | Changhai HospitalOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT05532319 | HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC(FRONT-1) | completed | Phase 2 | 64 | Guangxi Medical UniversityOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT05898854 | [68Ga]Ga-FAPI PET/CT in Gastric and Gastroesophageal Junctional Cancer | completed | Phase 2 | 20 | Aalborg University HospitalOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07304388 | HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC | completed | Phase 2 | 96 | Sun Yat-sen UniversityOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT01658878 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer(CheckMate040) | completed | Phase 1 / Phase 2 | 657 | Bristol-Myers SquibbINDUSTRY | 13 | Dec 24, 2025 | clinicaltrials |
| NCT03745794 | Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery | completed | Phase 2 | 136 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT05024513 | Biliary Drainage Plus HAIC in Locally Advanced pCCA | completed | Phase 2 | 127 | Peking UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05342636 | A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) | completed | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Dec 17, 2025 | clinicaltrials |
| NCT03910387 | Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer | completed | Phase 2 | 23 | Emory UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05001347 | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors | completed | Phase 2 | 25 | I-Mab Biopharma US LimitedINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05419362 | GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer | completed | Phase 2 | 42 | Genome & CompanyINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT04798781 | Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma | completed | Phase 2 | 16 | Andrew Hendifar, MDOTHER | 1 | Dec 11, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 2, 2026source: clinicaltrials